Biogen Idec

Biogen shortens name, raises hopes

Biogen Idec, which was heralded last week for results of an Alzheimer's drug trial, has shortened its name and chosen a new logo. It will now be known as Biogen (Nasdag: BIIB).

MS drug Tecfidera approved, awaited


The approval of Biogen Idec's MS therapy Tecfidera follows months of breathless Wall Street hype, and it looks like doctors are psyched for the drug, too. In a MedLIVE PULSE survey conducted by WorldOne Interactive, 40% of U.S neurologists polled said they're currently warehousing patients in anticipation of the new multiple sclerosis drug.